THE EFFECT OF LIPOSOMALLY CONJUGATED METHOTREXATE UPON MEDIATOR RELEASE FROM HUMAN PERIPHERAL BLOOD MONOCYTES
| Autor: | Nick Amos, A. M. Cooper, Y. L. Punn, Anwen Sian Williams, Bryan D. Williams |
|---|---|
| Rok vydání: | 1995 |
| Předmět: |
Lipopolysaccharides
musculoskeletal diseases Cell Survival medicine.medical_treatment Pharmacology Rheumatology Humans Medicine Pharmacology (medical) skin and connective tissue diseases Drug Carriers Liposome Tumor Necrosis Factor-alpha business.industry Monocyte Interleukin Biological activity Methotrexate medicine.anatomical_structure Cytokine Liposomes Immunology Leukocytes Mononuclear Tumor necrosis factor alpha business Drug carrier Interleukin-1 medicine.drug |
| Zdroj: | Rheumatology. 34:241-245 |
| ISSN: | 1462-0332 1462-0324 |
| Popis: | The ability of methotrexate (MTX) and a liposomal preparation containing a lipophilic conjugate of methotrexate (MTX-LIPO) to modulate pro-inflammatory mediator release from lipopolysaccharide-stimulated human peripheral blood monocytes was investigated. At non-toxic concentrations MTX-LIPO (10 micrograms MTX per 250 micrograms lipid) was a potent inhibitor of both IL-1 beta and TNF release resulting in 70.07 +/- 2.3% and 59.19 +/- 2.36% (mean +/- S.E.M.) inhibition, respectively, whereas empty liposomes (E-LIPO; 250 micrograms lipid/well) of the same lipid composition and free MTX (up to 100 micrograms/well) had no effect on either mediator. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|